A Phase 1 interventional study of Evobrutinib and Carbamazepine in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to investigate the effect of multiple doses of carbamazepine on two single doses of evobrutinib pharmacokinetics (PK) in healthy participants. Study details included:
Study Duration: up to 54 days. Treatment Duration: 25 days. Visit Frequency: Participants were residents in the Clinical Research Unit from Day 1 to Day 20 and returned on Day 26 for a Safety Follow-Up visit.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of Evobrutinib 45 mg on Day 1 and Day 19 under fed condition followed by Cabamazepine 100 mg on Days 2 and 3, 200 mg on Days 4 and 5 and then 300 mg from Days 6 to 19 and were titrated back to 200 mg from Days 20 to 22 and 100 mg on Days 23 to 25 twice daily.
Drug: Evobrutinib · Drug: Carbamazepine
Participants received a single oral dose of Evobrutinib 45 mg on Day 1 and Day 19
Also known as: M2951
Participants received Carbamazepine 100 mg on Days 2 and 3, 200 mg on Days 4 and 5 and then 300 mg from Days 6 to 19 and were titrated back to 200 mg from Days 20 to 22 and 100 mg on Days 23 to 25 twice daily.
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib
Cmax was obtained from plasma concentration time curve.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 16 and 24 hours post dose on Day 1 and Day 19.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. A serious adverse event (SAE) was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs."
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values
Blood samples were collected to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Hemoglobin Levels
Blood samples were collected to analyze the hematology parameter: Hemoglobin levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Hematocrit Values
Blood samples were collected to analyze the hematology parameter: Hematocrit Value. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Activated Partial Thromboplastin Time
Blood samples were collected to analyze the hematology parameter: Activated Partial Thromboplastin Time. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Change From Baseline in Hematology Parameters: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/ Leukocytes, and Neutrophils/Leukocytes
Blood samples were collected to analyze the hematology parameter: basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/ leukocytes, and neutrophils/leukocytes. The data in terms of 'percentage of cells' was calculated as: Count of Basophils (10\^9 cells/L) (or any other defined hematology parameter e.g. Neutrophils, Eosinophils etc.) divided by the total count of Leukocytes (10\^9 cells/L) in the blood multiplied by 100."
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio
Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value. Percent=Fraction×100
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Biochemistry Parameter: Bilirubin, Creatinine and Urate
Blood samples were collected to analyze the Biochemistry Parameter: Bilirubin, Creatinine and Urate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels
Blood samples were collected to analyze the Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Biochemistry Parameter: Protein and Albumin Levels
Blood samples were collected to analyze the Biochemistry Parameter: Protein and Albumin Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase
Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate Levels
Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in 12-Lead ECG Parameter: Heart Rate
12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: Heart Rate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in 12-Lead ECG Parameter: RR Duration, QT Duration, Fridericia's Formula (QTcF), PR Duration and QRS Duration
12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: RR Duration. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Vital Sign: Blood Pressure
Blood pressure (systolic and diastolic) was measured after at least 5 minutes resting, with the participant in the seated position without distractions.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Vital Sign: Pulse Rate
Pulse rate was measured after at least 5 minutes resting, with the subject in the seated position without distractions.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Vital Sign: Respiratory Rate
Respiratory Rate was measured after at least 5 minutes resting, with the participant in the seated position without distractions.
Time frame: Baseline (Day 1) and Day 26
Absolute Change From Baseline in Vital Sign: Body Temperature
The absolute changes from baseline in Body Temperature (degree Celsius \[°C\]) were reported.
Time frame: Baseline Day 1 and Day 26
Total Body Clearance of Evobrutinib From Plasma (CL/f)
CL/f was defined as the apparent total clearance of the drug from plasma after extravascular administration.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Apparent Volume of Distribution (Vz/f) of Evobrutinib
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. The apparent volume of distribution during the terminal phase following extravascular administration and was calculated by using the formula=Dose/ (AUC0-inf\* λz).
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Evobrutinib
The AUC from time zero (= dosing time) to the time of the last quantifiable concentration (tlast).
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib
Tmax was obtained directly from the concentration versus time curve.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Apparent Terminal Half-Life (t1/2) of Evobrutinib in Plasma
t1/2 was defined as the time taken for the plasma concentration or the amount of drug in the body to be reduced by half. Terminal half-life calculated by natural log 2 divided by lambda z.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (LOQ) (AUC0-tlast) of Evobrutinib Metabolite (MSC2729909A)
The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration was at or above LOQ. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)
Cmax was obtained from plasma concentration time curve.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib Metabolite (MSC2729909A)
Tmax was obtained directly from the concentration versus time curve.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Time Prior to the First Quantifiable (Non-zero) Concentration (Tlag) of Evobrutinib Metabolite (MSC2729909A) in Plasma
The time prior to the first concentration at or above limit of quantification. It is calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Metabolite to Parent Ratios for Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A)
Molecular weight-corrected ratio of metabolite (M) AUC0-inf to parent (P) AUC0-inf: M/P(AUC0-inf) = (AUC0-inf metabolite (MSC2729909A) \*molecular weight (MW) parent) / (AUC0-inf parent\*MW metabolite (MSC2729909A)).
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12,16 and 24 hours post dose on Day 1 and Day 19.
Metabolite to Parent Ratios for Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A)
Molecular weight-corrected ratio of metabolite Cmax to parent Cmax: M/P(Cmax) = (Cmaxmetabolite (MSC2729909A) \* MWparent) / (Cmax parent \* MW metabolite (MSC2729909A)).
Time frame: Evobrutinib: Predose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12,16 and 24 hours post dose on Day 1 and Day 19.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity
AE was defined as any untoward medical occurrence in a subject. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. SAE was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs. Severity of AE were assessed by the investigator as Mild, Moderate, and Severe: An event that prevents normal everyday activities. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe. SAS is used.
Time frame: Baseline (Day 1) and Day 26
| Milestone | Evobrutinib + Carbamazepine |
|---|---|
| Started | 14 |
| Completed | 12 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Elevated gamma-glutamyl transferase (ggt) | 1 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| Hour*nanograms per milliliter (h*ng/mL) | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib | 310 ± 33.2 | 49.2 ± 23.1 |
Cmax was obtained from plasma concentration time curve.
| nanogram per milliliter (ng/mL) | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Evobrutinib | 132 ± 33.1 | 22.4 ± 33.1 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. A serious adverse event (SAE) was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs."
| Participants | Evobrutinib + Carbamazepine |
|---|---|
| Any TEAE | 14 |
| Any serious TEAE | 0 |
Blood samples were collected to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, and Lymphocytes Values. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| 10^9 cells/Liter | Evobrutinib + Carbamazepine |
|---|---|
| Platelets | 11 ± 34.0 |
| Leukocytes | -0.23 ± 0.836 |
| Neutrophils | -0.18 ± 0.857 |
| Eosinophils | 0.04 ± 0.064 |
| Basophils | 0.03 ± 0.027 |
| Monocytes | -0.00 ± 0.111 |
| Lymphocytes | -0.12 ± 0.541 |
Blood samples were collected to analyze the hematology parameter: Hemoglobin levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| grams per liter (g/L) | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Hematology Parameter: Hemoglobin Levels | -5.178 ± 8.4346 |
Blood samples were collected to analyze the hematology parameter: Hematocrit Value. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| litre of cells per litre of blood (L/L) | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Hematology Parameter: Hematocrit Values | -0.014 ± 0.0236 |
Blood samples were collected to analyze the hematology parameter: Activated Partial Thromboplastin Time. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| seconds | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Hematology Parameter: Activated Partial Thromboplastin Time | -0.6 ± 1.29 |
Blood samples were collected to analyze the hematology parameter: basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/ leukocytes, and neutrophils/leukocytes. The data in terms of 'percentage of cells' was calculated as: Count of Basophils (10\^9 cells/L) (or any other defined hematology parameter e.g. Neutrophils, Eosinophils etc.) divided by the total count of Leukocytes (10\^9 cells/L) in the blood multiplied by 100."
| Percentage of cells | Evobrutinib + Carbamazepine |
|---|---|
| Basophils/Leukocytes | 0.5 ± 0.44 |
| Eosinophils/Leukocytes | 0.7 ± 0.98 |
| Lymphocytes/Leukocytes | 0.1 ± 7.80 |
| Monocytes/Leukocytes | 0.3 ± 2.11 |
| Neutrophils/Leukocytes | -1.6 ± 8.95 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| Picograms | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin | 0.35557 ± 0.506080 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| Femtoliter | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume | 1.4 ± 0.93 |
Blood samples were collected to analyze the hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value. Percent=Fraction×100
| percent | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio | -0.04 ± 0.041 |
Blood samples were collected to analyze the Biochemistry Parameter: Bilirubin, Creatinine and Urate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| micromole/liter (umol/L) | Evobrutinib + Carbamazepine |
|---|---|
| Bilirubin | -4.9 ± 2.91 |
| Creatinine | -1 ± 8.2 |
| Urate | -34.6 ± 59.35 |
Blood samples were collected to analyze the Biochemistry Parameter: Sodium, Potassium, Calcium, Magnesium and Phosphate Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| Millimoles per litre (mmol/L) | Evobrutinib + Carbamazepine |
|---|---|
| Sodium Levels | 1 ± 1.6 |
| Potassium Levels | 0.49 ± 0.407 |
| Calcium Levels | 0.02 ± 0.084 |
| Magnesium Levels | 0.05 ± 0.048 |
| Phosphate Levels | 0.04 ± 0.210 |
Blood samples were collected to analyze the Biochemistry Parameter: Protein and Albumin Levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| g/L | Evobrutinib + Carbamazepine |
|---|---|
| Protein | -4 ± 4.1 |
| Albumin | 2.3 ± 2.61 |
Biochemistry Parameter: Alkaline Phosphatase, Amylase, Lipase, Creatinine Kinase, Gamma Glutamyl Transferase Levels, Lactate Dehydrogenase, Aspartate Aminotransferase. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| Units per litre (U/L) | Evobrutinib + Carbamazepine |
|---|---|
| Alkaline Phosphatase | 8 ± 11 |
| Amylase | 1 ± 9.1 |
| Lipase | 2 ± 3.48 |
| Creatine Kinase | -33 ± 69.1 |
| Gamma Glutamyl Transferase | 56 ± 49.4 |
| Lactate Dehydrogenase | -1 ± 22.1 |
| Aspartate Aminotransferase | 9 ± 14.3 |
Biochemistry Parameter: Glucose, Chloride, Cholesterol, Triglycerides, Phosphate levels. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| mmol/L | Evobrutinib + Carbamazepine |
|---|---|
| Glucose | 0.01 ± 0.439 |
| Chloride | 2 ± 1.5 |
| Cholesterol | 0.4 ± 0.60 |
| Triglycerides | 0.2 ± 0.58 |
| Phosphate | 0.04 ± 0.210 |
12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: Heart Rate. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| beats per minute | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in 12-Lead ECG Parameter: Heart Rate | 2 ± 6.6 |
12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. 12-Lead ECG Parameter: RR Duration. Baseline was the last scheduled measurement before administration of study intervention. Absolute changes from baseline were calculated by subtracting the post-dose visit value from the Baseline value.
| Millisecond (msec) | Evobrutinib + Carbamazepine |
|---|---|
| RR Duration | -29 ± 94.9 |
| QT Duration | -1 ± 8.7 |
| QTcF | 2 ± 8.8 |
| PR Duration | -2 ± 7.5 |
| QRS Duration | -1 ± 3.9 |
Blood pressure (systolic and diastolic) was measured after at least 5 minutes resting, with the participant in the seated position without distractions.
| Millimeters of mercury (mmHg) | Evobrutinib + Carbamazepine |
|---|---|
| Systolic Blood Pressure | -2 ± 8.6 |
| Diastolic Blood Pressure | -2 ± 4.8 |
Pulse rate was measured after at least 5 minutes resting, with the subject in the seated position without distractions.
| beats per min | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Vital Sign: Pulse Rate | 2 ± 7.3 |
Respiratory Rate was measured after at least 5 minutes resting, with the participant in the seated position without distractions.
| breaths per minute | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Vital Sign: Respiratory Rate | -1 ± 3.3 |
The absolute changes from baseline in Body Temperature (degree Celsius \[°C\]) were reported.
| Degree Celsius | Evobrutinib + Carbamazepine |
|---|---|
| Absolute Change From Baseline in Vital Sign: Body Temperature | 0.1 ± 0.33 |
CL/f was defined as the apparent total clearance of the drug from plasma after extravascular administration.
| Litres per hour (L/h) | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Total Body Clearance of Evobrutinib From Plasma (CL/f) | 145 ± 33.2 | 914 ± 23.1 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. The apparent volume of distribution during the terminal phase following extravascular administration and was calculated by using the formula=Dose/ (AUC0-inf\* λz).
| Liter | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Apparent Volume of Distribution (Vz/f) of Evobrutinib | 373 ± 20.0 | 1218 ± 28.4 |
The AUC from time zero (= dosing time) to the time of the last quantifiable concentration (tlast).
| h*ng/mL | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Evobrutinib | 308 ± 33.4 | 46.1 ± 27.1 |
Tmax was obtained directly from the concentration versus time curve.
| hours | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib | 2.00 (0.500 to 4.00) | 2.00 (1.50 to 3.00) |
t1/2 was defined as the time taken for the plasma concentration or the amount of drug in the body to be reduced by half. Terminal half-life calculated by natural log 2 divided by lambda z.
| hours | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Apparent Terminal Half-Life (t1/2) of Evobrutinib in Plasma | 1.64 (0.997 to 2.89) | 0.961 (0.652 to 1.22) |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hour*ng/mL | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A) | 115 ± 19.6 | 57.1 ± 20.1 |
The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration was at or above LOQ. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
| h*ng/mL | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (LOQ) (AUC0-tlast) of Evobrutinib Metabolite (MSC2729909A) | 113 ± 19.7 | 55.7 ± 21.3 |
Cmax was obtained from plasma concentration time curve.
| nanograms per milliliters (ng/mL) | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A) | 30.2 ± 23.4 | 21.0 ± 20.0 |
Tmax was obtained directly from the concentration versus time curve.
| hours | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Time to Reach the Maximum Plasma Concentration (Tmax) of Evobrutinib Metabolite (MSC2729909A) | 2.50 (0.500 to 4.0) | 2.50 (1.50 to 4.00) |
The time prior to the first concentration at or above limit of quantification. It is calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.
| hours | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Time Prior to the First Quantifiable (Non-zero) Concentration (Tlag) of Evobrutinib Metabolite (MSC2729909A) in Plasma | 0.500 (0 to 1.52) | 0.500 (0 to 1.50) |
Molecular weight-corrected ratio of metabolite (M) AUC0-inf to parent (P) AUC0-inf: M/P(AUC0-inf) = (AUC0-inf metabolite (MSC2729909A) \*molecular weight (MW) parent) / (AUC0-inf parent\*MW metabolite (MSC2729909A)).
| Ratio | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Metabolite to Parent Ratios for Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Evobrutinib Metabolite (MSC2729909A) | 0.344 ± 31.0 | 1.11 ± 21.7 |
Molecular weight-corrected ratio of metabolite Cmax to parent Cmax: M/P(Cmax) = (Cmaxmetabolite (MSC2729909A) \* MWparent) / (Cmax parent \* MW metabolite (MSC2729909A)).
| Ratio | Evobrutinib | Evobrutinib + Carbamazepine |
|---|---|---|
| Metabolite to Parent Ratios for Maximum Observed Plasma Concentration (Cmax) of Evobrutinib Metabolite (MSC2729909A) | 0.213 ± 23.6 | 0.870 ± 20.9 |
AE was defined as any untoward medical occurrence in a subject. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. SAE was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE's were those events with onset dates on or after the first administration of study intervention. TEAEs include both Serious TEAEs and non-serious TEAEs. Severity of AE were assessed by the investigator as Mild, Moderate, and Severe: An event that prevents normal everyday activities. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe. SAS is used.
| Participants | Evobrutinib + Carbamazepine |
|---|---|
| Mild | 14 |
| Moderate | 7 |
| Severe | 0 |
Collected over Baseline (Day 1) up to Day 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Evobrutinib + Carbamazepine | 0/14 (0%) | 0/14 (0%) | 14/14 (100%) |
| Event | Evobrutinib + Carbamazepine |
|---|---|
| DizzinessNervous system disorders | 7/14 |
| SomnolenceNervous system disorders | 7/14 |
| NauseaGastrointestinal disorders | 6/14 |
| HeadacheNervous system disorders | 6/14 |
| ConstipationGastrointestinal disorders | 3/14 |
| VomitingGastrointestinal disorders | 3/14 |
| FatigueGeneral disorders | 3/14 |
| AstheniaGeneral disorders | 2/14 |
| Coordination abnormalNervous system disorders | 2/14 |
| DiplopiaEye disorders | 1/14 |
| Age, Continuous(Years) | Evobrutinib + Carbamazepine |
|---|---|
| Mean | 43 ± 11.5 |
| Sex: Female, Male(Participants) | Evobrutinib + Carbamazepine |
|---|---|
| Female | 2 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | Evobrutinib + Carbamazepine |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Evobrutinib + Carbamazepine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Ran from Jan 2022 to primary completion in Jul 2022, 6 months.
Results were first posted in Jan 2026, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →